placebo to QGE031 120 mg/ mL solution for injection in pre-filled syringe clinical trials

A three-year, multi-center, double-blind, extension study to evaluate the long-term safety and efficacy of ligelizumab in patients who completed ligelizumab’s Phase III studies in food allergy

This three-year study is looking at a new medicine called ligelizumab for food allergy. It's checking how safe it is and how well it works over a long time in people who have already taken part in earlier studies for this medicine.